Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation [0.03%]
移植前使用Blinatumomab与成人急性淋巴细胞白血病allo-HCT后复发率降低和无病生存期改善相关
Anush A Ginosyan,Karam Ashouri,Tiffany Chen et al.
Anush A Ginosyan et al.
Background: Adults with B-cell acute lymphoblastic leukemia (B-ALL) have inferior survival compared with pediatric patients, and pretransplant measurable residual disease (MRD) predicts relapse after allogeneic hematopoie...
Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies [0.03%]
麦福酚联合地塞米松治疗接受过免疫疗法的复发/难治性多发性骨髓瘤患者的现实世界结果
David Martínez-Campuzano,Clara Sopeña,María José Moreno et al.
David Martínez-Campuzano et al.
Introduction: The combination of melphalan fluflenamide (melflufen) and dexamethasone (melf-dex) is approved for patients with relapsed/refractory multiple myeloma (RRMM) after ≥3 prior lines of therapy; however, the res...
Joseph G Schroers-Martin,Ranjana Advani
Joseph G Schroers-Martin
Early-stage classic Hodgkin lymphoma (cHL) is characterized by high cure rates, with current treatment paradigms focused on personalizing therapy to balance disease control with the avoidance of long-term toxicity. Established response-adap...
Efficacy and Safety of Mogamulizumab for Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis [0.03%]
莫加穆利单抗治疗皮肤T细胞淋巴瘤疗效和安全性的系统评价和 meta 分析
Ayomide Lawal,Amanda Ribeiro Rangel,Advait Raja et al.
Ayomide Lawal et al.
Cutaneous T-cell lymphomas (CTCL) are heterogeneous skin malignancies. Mycosis fungoides (MF), followed by Sézary syndrome (SS), are the most prevalent. Mogamulizumab demonstrated a superior overall response rate (ORR) compared to vorinost...
Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis [0.03%]
CD38抗体在高危新诊断多发性骨髓瘤中的应用：一项 meta 分析
Divaya Bhutani,Yusha Liu,Rajshekhar Chakraborty et al.
Divaya Bhutani et al.
The anti-CD38 monoclonal antibodies Daratumumab and Isatuximab are both approved for use in patients with newly diagnosed multiple myeloma (NDMM) in both the transplant-eligible and transplant-ineligible setting. However, the degree to whic...
Monoclonal Gammopathy of Clinical Significance: A Multisystem Disorder Requiring a Multidisciplinary Approach [0.03%]
具有临床意义的单克隆免疫球蛋白血症：一种需要多学科协作的系统性疾病
Meletios Athanasios Dimopoulos,Foteini Theodorakakou,Efstathios Kastritis
Meletios Athanasios Dimopoulos
Monoclonal gammopathy of clinical significance (MGCS) has emerged as a clinically important but underrecognized category of clonal plasma cell or B-cell disorders that manifest with significant organ dysfunction in the absence of malignancy...
BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function [0.03%]
桥接研究（OP-107）：一项在肾功能损害的复发难治多发性骨髓瘤患者中评估Melflufen联合地塞米松的药代动力学Ⅱ期研究
Ludek Pour,Sosana Delimpasi,Wojciech Legiec et al.
Ludek Pour et al.
Background: Information about safety and pharmacokinetics (PK) of melflufen (melphalan flufenamide) is limited in renal impairment (RI) patients. The BRIDGE study evaluated the impact of renal function on PK of the main a...
Bispecific Antibody Therapy With Elranatamab for Refractory Waldenström Macroglobulinemia: A Case Report [0.03%]
针对复发/难治瓦尔登斯特伦巨球蛋白血症的双特异性抗体Elranatamab治疗：一例报告
Varun Nandakumar,Amandeep Godara,Felix Mensah
Varun Nandakumar
Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies [0.03%]
四重预处理/ refractory多发性骨髓瘤：既往接受过抗 CD38、IMiDs、蛋白酶体抑制剂和BCMA靶向治疗的患者
Magdalena Olszewska-Szopa,David H Vesole,Artur Jurczyszyn
Magdalena Olszewska-Szopa
Current treatment regimens for multiple myeloma, both in patients eligible and ineligible for autologous stem cell transplantation without adverse biological features (standard risk cytogenetics; absence of extramedullary disease, normal re...
An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404 [0.03%]
伊布替尼联合伊沙佐米治疗复发难治性套细胞淋巴瘤的PrE0404研究
Jonathon B Cohen,Craig A Portell,Mehdi Hamadani et al.
Jonathon B Cohen et al.
Introduction: Management of relapsed mantle cell lymphoma (MCL) has included Bruton's tyrosine kinase (BTK) inhibitors for more than 10 years, but finding an optimal combination partner that meaningfully improves outcomes...